Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 2
2006 2
2008 3
2009 5
2010 4
2011 1
2012 2
2013 6
2014 5
2015 9
2016 7
2017 6
2018 5
2019 10
2020 9
2021 8
2022 8
2023 9
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

93 results

Results by year

Filters applied: . Clear all
Page 1
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.
Horwitz S, O'Connor OA, Pro B, Illidge T, Fanale M, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Feldman T, Lennard A, Belada D, Illés Á, Tobinai K, Tsukasaki K, Yeh SP, Shustov A, Hüttmann A, Savage KJ, Yuen S, Iyer S, Zinzani PL, Hua Z, Little M, Rao S, Woolery J, Manley T, Trümper L; ECHELON-2 Study Group. Horwitz S, et al. Lancet. 2019 Jan 19;393(10168):229-240. doi: 10.1016/S0140-6736(18)32984-2. Epub 2018 Dec 4. Lancet. 2019. PMID: 30522922 Free PMC article. Clinical Trial.
Claiming the mantle of the brain.
Ruan J. Ruan J. Blood. 2022 Oct 27;140(17):1835-1836. doi: 10.1182/blood.2022017285. Blood. 2022. PMID: 36301632 Free article. No abstract available.
A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas.
Moskowitz AJ, Ghione P, Jacobsen E, Ruan J, Schatz JH, Noor S, Myskowski P, Vardhana S, Ganesan N, Hancock H, Davey T, Perez L, Ryu S, Santarosa A, Dowd J, Obadi O, Pomerantz L, Yi N, Sohail S, Galasso N, Neuman R, Liotta B, Blouin W, Baik J, Geyer MB, Noy A, Straus D, Kumar P, Dogan A, Hollmann T, Drill E, Rademaker J, Schoder H, Inghirami G, Weinstock DM, Horwitz SM. Moskowitz AJ, et al. Among authors: ruan j. Blood. 2021 Dec 30;138(26):2828-2837. doi: 10.1182/blood.2021013379. Blood. 2021. PMID: 34653242 Free PMC article. Clinical Trial.
Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL.
Ruan J, Moskowitz A, Mehta-Shah N, Sokol L, Chen Z, Kotlov N, Nos G, Sorokina M, Maksimov V, Sboner A, Sigouros M, van Besien K, Horwitz S, Rutherford SC, Mulvey E, Revuelta MV, Xiang J, Alonso A, Melnick A, Elemento O, Inghirami G, Leonard JP, Cerchietti L, Martin P. Ruan J, et al. Blood. 2023 May 4;141(18):2194-2205. doi: 10.1182/blood.2022018254. Blood. 2023. PMID: 36796016 Free PMC article. Clinical Trial.
IMiDs New and Old.
Yamshon S, Ruan J. Yamshon S, et al. Among authors: ruan j. Curr Hematol Malig Rep. 2019 Oct;14(5):414-425. doi: 10.1007/s11899-019-00536-6. Curr Hematol Malig Rep. 2019. PMID: 31302872 Review.
Update on T-Cell Lymphoma Epidemiology.
Chen JJ, Tokumori FC, Del Guzzo C, Kim J, Ruan J. Chen JJ, et al. Among authors: ruan j. Curr Hematol Malig Rep. 2024 Mar 7. doi: 10.1007/s11899-024-00727-w. Online ahead of print. Curr Hematol Malig Rep. 2024. PMID: 38451372 Review.
93 results